Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 5/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 6/20 | 0.37 |
| ▸ | REN | P00797 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PEPD | P12955 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | THPO | P40225 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18878678 | 1.00 | F2 (0.41) | F2CNR1CNR2RAB9APOLB | |
| SCHEMBL18875724 | 1.00 | F2 (0.41) | F2CNR1CNR2RAB9APOLB | |
| SCHEMBL18875644 | 1.00 | F2 (0.41) | F2CNR1CNR2RAB9APOLB | |
| SCHEMBL7022185 | 1.00 | F2 (0.41) | F2CNR1CNR2RAB9APOLB | |
| SCHEMBL18875725 | 1.00 | F2 (0.41) | F2CNR1CNR2RAB9APOLB | |
| SCHEMBL18875713 | 1.00 | F2 (0.41) | F2CNR1CNR2RAB9APOLB | |
| SCHEMBL18875546 | 1.00 | F2 (0.41) | F2CNR1CNR2RAB9APOLB | |
| SCHEMBL18875527 | 1.00 | F2 (0.41) | F2CNR1CNR2RAB9APOLB | |
| SCHEMBL4597804 | 0.95 | CNR1 (0.46) | F2CNR1CNR2RAB9APOLB | |
| SCHEMBL4813682 | 0.95 | CNR1 (0.46) | F2CNR1CNR2RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0346847-A2 | Amino acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1989-12-20 | — | — | EP | claimed |
| US-11834447-B2 | Indole derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20200407338-A1 | ISOQUINOLINE DERIVATIVES AND USE THEREOF | PURDUE PHARMA LP (US) | 2020-12-31 | — | — | US | disclosed |
| US-10730866-B2 | Indole derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2020-08-04 | — | — | US | disclosed |
| US-10005768-B2 | Carboxamide derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180134690-A1 | INDAZOLES AND USE THEREOF | PURDUE PHARMA LP (US) | 2018-05-17 | — | — | US | disclosed |
| US-20180134690-A1 | INDAZOLES AND USE THEREOF | PURDUE PHARMA LP (US) | 2018-05-17 | — | — | US | disclosed |
| US-20170283392-A1 | DIBENZAZEPINE DERIVATIVES AND USE THEREOF | PURDUE PHARMA L.P. | 2017-10-05 | — | — | US | disclosed |
| US-20170283392-A1 | DIBENZAZEPINE DERIVATIVES AND USE THEREOF | PURDUE PHARMA L.P. | 2017-10-05 | — | — | US | disclosed |
| US-9745287-B2 | Pyrimidines and use thereof | PURDUE PHARMA L.P. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20060166895-A1 | Retroviral protease inhibitors | MONSANTO COMPANY (NOW NAMED PHARMACIA CORPORATION, WHICH IS A WHOLLY OWNED SUBSIDIARY OF PFIZER, INC (US) | 2006-07-27 | — | — | US | disclosed |
| US-7026485-B2 | Retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-04-11 | — | — | US | disclosed |
| US-20050004230-A1 | Retroviral protease inhibitors | MONSANTO COMPANY (NOW NAMED PHARMACIA CORPORATION, WHICH IS A WHOLLY OWNED SUBSIDIARY OF PFIZER, INC (US) | 2005-01-06 | — | — | US | disclosed |
| US-6762187-B2 | HETEROCYCLIC NITROGEN COMPOUNDS USED AS ENZYME INHIBITORS FOR PROPHYLAXIS OF HUMAN IMMUNODEFICIENCY VIRUS(HIV) | MONSANTO COMPANY | 2004-07-13 | — | — | US | disclosed |
| US-6506759-B1 | Method for treating HIV-related AIDS comprising administering an effective amount of a composition N-heterocyclic moiety containing hydroxyethylamine compounds are effective as retroviral protease inhibitors, and in | MONSANTO COMPANY | 2003-01-14 | — | — | US | disclosed |
| US-6180646-B1 | PREVENT REPRODUCTION OF RETROVIRUS | MONSANTO COMPANY | 2001-01-30 | — | — | US | disclosed |
| US-5446161-A | Protease inhibitor, viricides | HOFFMANN-LA ROCHE INC. (US) | 1995-08-29 | — | — | US | disclosed |
| EP-0641325-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1995-03-08 | — | — | EP | disclosed |
| EP-0346847-B1 | Amino acid derivatives | HOFFMANN LA ROCHE (CH) | 1994-05-11 | — | — | EP | disclosed |
| EP-0346847-A2 | Amino acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1989-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834447-B2 | Indole derivatives and use thereof | TRPC4, TRPV4, TRPV1 | F2 1100/4885CNR1 82/4885CNR2 99/4885 |
| US-20170283392-A1 | DIBENZAZEPINE DERIVATIVES AND USE THEREOF | CACNA1A, CACNA1D, CACNA1S | F2 955/4885CNR1 143/4885CNR2 159/4885 |
| US-10005768-B2 | Carboxamide derivatives and use thereof | TRPV1, CACNA1A, SCN10A | F2 3099/4885CNR1 96/4885CNR2 51/4885 |
| US-20200407338-A1 | ISOQUINOLINE DERIVATIVES AND USE THEREOF | KCNQ3, KCNQ5, KCNQ4 | F2 834/4885CNR1 92/4885CNR2 100/4885 |
| US-20050004230-A1 | Retroviral protease inhibitors | MME, PREP, TMPRSS15 | F2 3794/4885CNR1 4206/4885CNR2 4710/4885 |
| US-10730866-B2 | Indole derivatives and use thereof | TRPC4, TRPV4, TRPV1 | F2 1100/4885CNR1 82/4885CNR2 99/4885 |
| US-20180134690-A1 | INDAZOLES AND USE THEREOF | TRPV3, TRPA1, TRPV1 | F2 1571/4885CNR1 109/4885CNR2 93/4885 |
| US-20060166895-A1 | Retroviral protease inhibitors | MME, PREP, TMPRSS15 | F2 3794/4885CNR1 4206/4885CNR2 4710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.